ERIS Lifesciences LtdNSE: ERIS
Open the ERIS Lifesciences Ltd page
Follow ERIS Lifesciences LtdFree account. Get a note when ERIS Lifesciences Ltd files.
Q1 FY27 results analysis · July 29, 2026

ERIS LIFESCIENCES LTD Q1 FY27 Results Analysis: PAT Surges 20.7%, Margin Compresses 2 ppt

+20.7%PAT year on year, Rs. 142.39 Cr
Cofacto ResearchPublished July 29, 20262 min readNeutral read
Quick summary

ERIS Lifesciences Ltd's Q1 FY27 numbers came in mixed, with revenue of Rs. 873.25 Cr (+12.97% YoY) and PAT growth of +20.68% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateJuly 29, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 873.25 Cr (+12.97% YoY)
PAT (Q1)Rs. 142.39 Cr (+20.68% YoY)
EBITDA margin33.88% (-200 bps YoY)
EPS (Q1)Rs. 10.28 (+18.71% YoY)
Market capRs. 19,818.35 Cr
CMPRs. 1,426.50

Quarter Snapshot

Eris delivered strong revenue growth of 13% YoY and PAT growth of 20.7%, but EBITDA margin compressed 2 ppt due to a material cost spike from product mix shift. Deleveraging continued with debt-equity improving to 0.64x, but the margin miss against the full-year guidance of 36% is a concern, though management had guided H1 weakness. The capex cycle for new facilities remains heavy.

Key Investment Insights

Key Positives

  • Revenue grew 13.0% YoY to Rs.873.25 Cr, the strongest quarterly print in several quarters.
  • PAT attributable to owners grew 20.7% YoY to Rs.142.39 Cr, outpacing EBITDA growth.
  • Debt-equity ratio improved to 0.64 from 0.74 a year ago, confirming deleveraging.
  • Interest service coverage ratio improved to 4.86× from 4.29×.
  • Net worth grew 16% YoY to Rs.3,944 Cr.

Risk Factors

  • EBITDA margin compressed 2.0 ppt YoY to 33.88%, driven by a 3.5 ppt increase in material cost as a share of revenue.
  • Total material cost rose 29.6% YoY against revenue growth of 13.0%, indicating product mix shift to lower-margin products.
  • Current ratio weakened to 0.60 from 0.93, reflecting working capital build-up.
  • The 33.88% EBITDA margin is below the full-year guidance of 36%, though management guided H1 lower than H2.

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.